Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers
F Waldmeier, U Glaenzel, B Wirz, L Oberer… - Drug metabolism and …, 2007 - ASPET
Aliskiren (2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamid
hemifumarate) is the first in a …
hemifumarate) is the first in a …
Pharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady …
F Waldmeier, GJ Bruin, U Glaenzel, K Hazell… - Drug Metabolism and …, 2010 - ASPET
Deferasirox (ICL670) is a novel once-daily, orally administered iron chelator to treat chronic
iron overload in patients with transfusion-dependent anemias. Absorption, distribution, …
iron overload in patients with transfusion-dependent anemias. Absorption, distribution, …
Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes …
U Glaenzel, Y Jin, R Nufer, W Li, K Schroer… - Drug metabolism and …, 2018 - ASPET
Siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is
currently being investigated for the treatment of secondary progressive multiple sclerosis. We …
currently being investigated for the treatment of secondary progressive multiple sclerosis. We …
Discovery of icenticaftor (QBW251), a cystic fibrosis transmembrane conductance regulator potentiator with clinical efficacy in cystic fibrosis and chronic obstructive …
…, L Edwards, B Everatt, U Glaenzel… - Journal of Medicinal …, 2021 - ACS Publications
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel
are established as the primary causative factor in the devastating lung disease cystic fibrosis (…
are established as the primary causative factor in the devastating lung disease cystic fibrosis (…
Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers
A James, L Blumenstein, U Glaenzel, Y Jin… - Cancer chemotherapy …, 2015 - Springer
Purpose To determine the pharmacokinetics of the p110α-selective inhibitor alpelisib (BYL719)
in humans, to identify metabolites in plasma and excreta, and to characterize pathways …
in humans, to identify metabolites in plasma and excreta, and to characterize pathways …
Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major …
U Glaenzel, Y Jin, R Hansen, K Schroer… - Drug Metabolism and …, 2020 - ASPET
Capmatinib (INC280), a highly selective and potent inhibitor of the MET receptor tyrosine
kinase, has demonstrated clinically meaningful efficacy and a manageable safety profile in …
kinase, has demonstrated clinically meaningful efficacy and a manageable safety profile in …
An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
…, Y Jin, H Borell, AF Roffel, U Glaenzel… - Pharmacology …, 2020 - Wiley Online Library
Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent
kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or …
kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or …
Absorption, distribution, metabolism, and excretion of the oral prostaglandin D2 receptor 2 antagonist fevipiprant (QAW039) in healthy volunteers and in vitro
…, Y Jin, JJ van Lier, VJ Erpenbeck, U Glaenzel… - Drug Metabolism and …, 2017 - ASPET
Fevipiprant is a novel oral prostaglandin D 2 receptor 2 (DP 2 ; also known as CRTh2)
antagonist, which is currently in development for the treatment of severe asthma and atopic …
antagonist, which is currently in development for the treatment of severe asthma and atopic …
Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro
…, G Zenke, AG Zimmerlin, U Glaenzel… - Drug metabolism and …, 2006 - ASPET
The absorption and disposition of pimecrolimus, a calcineurin inhibitor developed for the
treatment of inflammatory skin diseases, was investigated in four healthy volunteers after a …
treatment of inflammatory skin diseases, was investigated in four healthy volunteers after a …
Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy …
HP Gschwind, U Glaenzel, F Waldmeier, B Wirz… - European journal of …, 2012 - Elsevier
8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC), a compound lacking
pharmacological activity enhances the absorption of salmon calcitonin, when co-administered. …
pharmacological activity enhances the absorption of salmon calcitonin, when co-administered. …